Advertisement
STVN vs WST
Which Stock Would AI Choose? Stevanato Group S.p.A. (STVN) vs. West Pharmaceutical Services, Inc. (WST) Stock Comparison
Key Takeaways
- Both STVN and WST operate in the pharmaceutical containment and delivery systems sector, supplying components for injectable drugs and biologics.
- Recent market activity shows STVN trading near the middle of its 52-week range with moderate volatility, while WST maintains a higher valuation multiple amid steady demand.
- STVN reported 7% revenue growth in Q1 2026 (10% at constant currency), supported by high-value solutions, while WST delivered a 21% sales increase in its most recent quarter.
- Sector exposure to biologics and injectable therapeutics provides similar growth drivers, though WST benefits from broader scale and established customer relationships.
- Market sentiment for both remains tied to pharmaceutical industry spending and innovation in drug delivery, with limited divergence in recent weeks.
- Risk factors include currency fluctuations for STVN and potential margin pressures from raw material costs for WST.
Introduction
Stevanato Group S.p.A. (STVN) and West Pharmaceutical Services, Inc. (WST) represent two leading providers of specialized packaging and delivery solutions for the pharmaceutical and biotechnology industries. This comparison examines their business models, recent performance trends, and relative positioning in the current market environment. Institutional investors, sector-focused traders, and portfolio managers evaluating healthcare supply-chain exposure may find the analysis useful for assessing competitive dynamics and risk-adjusted opportunities between the two stocks.
STVN Overview and Recent Performance
Stevanato Group S.p.A. designs, manufactures, and distributes drug containment and delivery systems, including vials, syringes, and pen injectors, primarily serving biopharmaceutical and diagnostic clients. In recent weeks, the stock has traded in a relatively narrow range around $19, reflecting mixed sentiment following its Q1 2026 results that showed 7% revenue growth (10% at constant currency) driven by high-value solutions. A June 2026 product launch for a new pen injector targeting diabetes and weight-management applications provided a modest positive catalyst, though broader market activity has been influenced by sector rotation and currency movements affecting reported figures.
WST Overview and Recent Performance
West Pharmaceutical Services, Inc. specializes in primary packaging and delivery components for injectable therapeutics, with a global footprint serving pharmaceutical, biotechnology, and generic drug manufacturers. Recent market activity has seen the stock trade near $358, supported by Q1 2026 results that exceeded revenue expectations with 21% sales growth. Demand for containment systems tied to biologic therapies has contributed to stable performance, while the company’s scale and diversified customer base have helped moderate volatility compared with smaller peers amid fluctuating input costs and supply-chain dynamics.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots from a platform that offers hundreds of AI Trading Bots capable of trading thousands of different tickers. Only the strongest and most suitable bots for prevailing market conditions earn placement in this section, with available options demonstrating varied win rates typically ranging from 60% to over 80%, average trade durations from minutes to weeks, and profit factors often exceeding 1.5 depending on strategy and timeframe. These bots employ diverse trading styles, strategies, timeframes, performance metrics, and ticker sets. Review the full list to identify bots aligned with individual risk tolerance and objectives.
Head-to-Head Comparison
Both companies focus on high-margin components for injectable drug delivery, yet WST operates at greater scale with a wider product portfolio and more established global manufacturing footprint, resulting in typically higher market capitalization and valuation multiples. STVN exhibits stronger exposure to European markets and recent product innovation in pen injectors, which may support growth in specific therapeutic areas such as diabetes and weight management. Recent momentum has favored WST on absolute revenue beats, while STVN has shown resilience in constant-currency terms. Risk factors differ modestly: STVN faces greater currency translation exposure, whereas WST contends with potential raw-material cost pressures. Sector sentiment remains broadly constructive for both due to ongoing biologic drug development, though relative performance in recent weeks has been influenced by overall healthcare equity rotation rather than company-specific events.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings delivery, and relative positioning within the sector, Tickeron’s AI would currently assign a modest probabilistic preference to WST owing to its demonstrated revenue outperformance, larger scale, and more stable recent price behavior. STVN remains competitive on growth metrics and new-product catalysts, leaving room for either stock to outperform depending on pharmaceutical spending trends and macroeconomic conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is STVN is a Hold and WST is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
STVN’s FA Score shows that 0 FA rating(s) are green whileWST’s FA Score has 1 green FA rating(s).
- STVN’s FA Score: 0 green, 5 red.
- WST’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
STVN’s TA Score shows that 6 TA indicator(s) are bullish while WST’s TA Score has 6 bullish TA indicator(s).
- STVN’s TA Score: 6 bullish, 3 bearish.
- WST’s TA Score: 6 bullish, 3 bearish.
Price Growth
STVN (@Pharmaceuticals: Other) experienced а +0.86% price change this week, while WST (@Pharmaceuticals: Other) price change was +3.96% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.03%. For the same industry, the average monthly price growth was +0.09%, and the average quarterly price growth was -1.71%.
Reported Earning Dates
STVN is expected to report earnings on Aug 04, 2026.
WST is expected to report earnings on Oct 22, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+5.03% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| STVN | WST | STVN / WST | |
| Capitalization | 5.42B | 24B | 23% |
| EBITDA | 292M | 880M | 33% |
| Gain YTD | -1.342 | 24.210 | -6% |
| P/E Ratio | 33.94 | 43.66 | 78% |
| Revenue | 1.2B | 3.33B | 36% |
| Total Cash | 113M | 436M | 26% |
| Total Debt | 449M | 312M | 144% |
WST | ||
|---|---|---|
OUTLOOK RATING 1..100 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 47 | |
PRICE GROWTH RATING 1..100 | 41 | |
P/E GROWTH RATING 1..100 | 30 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| STVN | WST | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 78% |
| Stochastic ODDS (%) | 3 days ago 84% | 3 days ago 64% |
| Momentum ODDS (%) | 3 days ago 82% | 3 days ago 68% |
| MACD ODDS (%) | 3 days ago 83% | 3 days ago 54% |
| TrendWeek ODDS (%) | 3 days ago 79% | 3 days ago 68% |
| TrendMonth ODDS (%) | 3 days ago 80% | 3 days ago 62% |
| Advances ODDS (%) | 5 days ago 80% | 3 days ago 68% |
| Declines ODDS (%) | 3 days ago 79% | 10 days ago 58% |
| BollingerBands ODDS (%) | 3 days ago 72% | 3 days ago 81% |
| Aroon ODDS (%) | 3 days ago 82% | 3 days ago 61% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EJAN | 35.87 | 0.15 | +0.42% |
| Innovator Emerging Mkt Pwr Buff ETF™ Jan | |||
| HBR | 9.57 | N/A | N/A |
| CANARY CAPITAL GROUP | |||
| UTRE | 48.83 | -0.05 | -0.10% |
| F/m US Treasury 3 Year Note ETF | |||
| LQD | 106.25 | -0.16 | -0.15% |
| iShares iBoxx $ Invmt Grade Corp Bd ETF | |||
| JDVI | 39.51 | -0.14 | -0.35% |
| JHancock Discp Val Intl Sel ETF | |||
STVN and
Correlation & Price change
A.I.dvisor indicates that over the last year, STVN has been loosely correlated with WST. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if STVN jumps, then WST could also see price increases.
| Ticker / NAME | Correlation To STVN | 1D Price Change % | ||
|---|---|---|---|---|
| STVN | 100% | -1.73% | ||
| WST - STVN | 47% Loosely correlated | +0.40% | ||
| MTD - STVN | 37% Loosely correlated | +2.59% | ||
| NPCE - STVN | 35% Loosely correlated | -6.25% | ||
| BRKR - STVN | 35% Loosely correlated | -2.33% | ||
| NVST - STVN | 33% Loosely correlated | -1.69% | ||
More | ||||
WST and
Correlation & Price change
A.I.dvisor indicates that over the last year, WST has been loosely correlated with STVN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if WST jumps, then STVN could also see price increases.
| Ticker / NAME | Correlation To WST | 1D Price Change % | ||
|---|---|---|---|---|
| WST | 100% | +0.40% | ||
| STVN - WST | 46% Loosely correlated | -1.73% | ||
| XRAY - WST | 36% Loosely correlated | -2.69% | ||
| NVST - WST | 36% Loosely correlated | -1.69% | ||
| BLFS - WST | 35% Loosely correlated | -1.14% | ||
| QDEL - WST | 33% Loosely correlated | +1.21% | ||
More | ||||